文献速递治疗药物监测与药物基因组学

新兴生物分析方法用于药物浓度监测的临床价值:药物依从性与治疗药物监测适用性的范围综述

Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring.
PubMed 文献 · Drugs · 2021-11-01

该范围综述系统检索2000–2020年三个数据库,纳入175篇文献,评估干血斑、唾液和头发分析用于药物依从性监测(MAM)与治疗药物监测(TDM)的临床验证情况。结果显示多数报告集中于神经疾病、感染性疾病和移植领域,分别有62种和131种药物检测用于MAM和TDM,三种基质各有优劣但均具潜力,建议标准化临床验证以提升证据质量与可比性。

要点

  • 干血斑、唾液和头发分析可替代传统采血用于MAM和TDM。
  • 纳入175篇文献中,唾液研究66篇、干血斑57篇、头发55篇。
  • 多数报告涉及神经疾病(37%)、感染性疾病(31%)和移植(14%)。

核心结论

  • 不依赖传统侵入性采血即可实现MAM和TDM,干血斑、唾液和头发各有优劣但均具潜力。
  • 建议标准化方法的临床验证以增强未来证据的质量与可比性。

研究设计与样本

  • 范围综述,系统检索三个电子数据库2000–2020年文献,由两名独立评审在Rayyan中筛选,数据汇总于REDCap数据库。
  • 最终纳入175篇文章:干血斑57篇、唾液66篇、头发55篇。

主要发现

  • 报告最多的领域为神经疾病(37%)、感染性疾病(31%)和移植(14%)。
  • 62种药物检测应用于MAM,131种应用于TDM。
  • 生成了所有已测药物的临床验证概览。

关键数值与推荐

  • 临床有效性主要依据研究样本量、交叉验证方式和方描述进行评估。
  • 结果按基质、治疗领域和应用(MAM和/或TDM)报告。

临床怎么用

  • 临床可考虑采用干血斑、唾液或头发等微创/非侵入性基质替代传统血样进行药物浓度监测。
  • 选择具体方法时需结合药物特性、治疗领域及方法学验证程度综合判断。

局限性

  • 原文未报告具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Direct quantification of drug concentrations allows for medication adherence monitoring (MAM) and therapeutic drug monitoring (TDM). Multiple less invasive methods have been developed in recent years: dried blood spots (DBS), saliva, and hair analyses. AIM: To provide an overview of emerging drug quantification methods for MAM and TDM, focusing on the clinical validation of methods in patients prescribed chronic drug therapies. METHODS: A scoping review was performed using a systematic search in three electronic databases covering the period 2000-2020. Screening and inclusion were performed by two independent reviewers in Rayyan. Data from the articles were aggregated in a REDCap database. The main outcome was clinical validity of methods based on study sample size, means of cross-validation, and method description. Outcomes were reported by matrix, therapeutic area and application (MAM and/or TDM). RESULTS: A total of 4590 studies were identified and 175 articles were finally included; 57 on DBS, 66 on saliva and 55 on hair analyses. Most reports were in the fields of neurological diseases (37%), infectious diseases (31%), and transplantation (14%). An overview of clinical validation was generated of all measured drugs. A total of 62 drugs assays were applied for MAM and 131 for TDM. CONCLUSION: MAM and TDM are increasingly possible without traditional invasive blood sampling: the strengths and limitations of DBS, saliva, and hair differ, but all have potential for valid and more convenient drug monitoring. To strengthen the quality and comparability of future evidence, standardisation of the clinical validation of the methods is recommended.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Zijp TR, Izzah Z, Åberg C, et al. Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring. Drugs. 2021. PMID: 34724175. doi:10.1007/s40265-021-01618-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。